Hepatitis C is a liver disease which is transmitted by the contact with the blood of an infected person. Hepatitis C show significant genetic variation in population worldwide, due to high rate of viral RNA mutations. HCV has six variants (HCV genotypes 1, 2, 3, 4, 5, and 6), and 15 subtypes are recorded which vary in the rate of prevalence around the globe. Different types of devices are used for the diagnosis of hepatitis C, including HCV viral load test, HCV antibody test, HCV genotype test and liver biopsy. Inexpensive, rapid, robust, and sensitive analytical devices are essential for effective, accurate diagnosis and monitoring of disease treatment.

Increase in hepatitis C virus testing Market is mainly attributed to high incidence of chronic infection with hepatitis C virus. Furthermore, unhygienic blood donation practices are the considerable cause of spread of hepatitis C virus. Hepatitis C screening test is compulsory before the organ donation, increase in organ donation globally expected to boost the testing market growth. The increase in healthcare expenditure, changing lifestyle and increase in government initiatives are some of the key factors driving the growth of global hepatitis C virus antiviral Testing Market. In addition, growing healthcare awareness about the hepatitis C virus is also fueling the growth of global hepatitis C virus testing market. However, stringent regulation for approval of hepatitis C testing is the major factor expected to hamper the hepatitis C virus testing market.

Globally, hepatitis C virus testing market is segmented based on technique, test type, end-user.

Based on technique, hepatitis C virus testing market is segmented as:

Polymerase Chain Reaction Tests
Immunoassays
Others


Based on test, hepatitis C virus testing market is segmented as:

Hepatitis C antibody
Hepatitis C RNA quantitative test
Hepatitis C RNA qualitative test
Hepatitis C RIBA
Hepatitis C genotype
Viral load


Based on the end-user, hepatitis C virus testing market is segmented as:

Hospitals
Diagnostic Centres
Blood Donation centers


When compared to hepatitis A and hepatitis B Prevalence of hepatitis C is low. According to Institute of Liver and Biliary Sciences India (ILBS) around 3% of population globally, infected with hepatitis C virus, therefore minimum R&D investments by market players to develop new and effective hepatitis C virus tests. Among the all tests, HCV antibody testing is expected to occupy more share because antibody testing is the primarily used test for HCV testing. In end user segment, diagnostic centers is expected to have major market share in HCV testing market. Application of new electrochemical immune sensor and genosensor technologies in HPV testing are expected to change conventional HPV testing practices.

Geographically, hepatitis C virus testing Market is divided into Asia-Pacific, Latin America, North America, Europe and The Middle East and Africa. Europe hepatitis C market is expected to grow at significant rates owing to incidence of hepatitis C virus diseases. According to WHO European region have 1.5% and Eastern Mediterranean has 2.3% prevalence of HCV diseases that shows significant variations in genes in population globally due to high rates of mutation of viral RNA. Asia Pacific is expected to be having lucrative market growth over the forecasting period owing to disease prevalence rates.

Some of the players in global hepatitis C virus testing Market include Abbott Laboratories (U.S.), Bio Rad Laboratories Inc. (U.S.), Qiagen (Germany), Bayer AG (Switzerland), OraSure Technologies (U.S.), Siemens Healthcare GmbH (Germany), BioGenex (U.S.), H. Hoffman-La Roche Ltd (Switzerland), Thermo Fisher Scientific Inc. (U.S.), and Ortho Clinical Diagnostic Inc. (U.S.), among others.

In March 2017, Siemens Healthineer’s Versant HCV Genotype 2.0 line probe (LiPA) assay gained market approval from U.S. FDA for HCV testing


In October 2015, Hologic received CE?IVD certification for its Aptima? HCV (hepatitis C virus) Quant Dx assay on the fully automated Panther? system


In May 2011, Abbott’s RealTime PCR (polymerase chain reaction) test received testing market approval from the U.S. Food and Drug Administration for measuring the viral load of hepatitis C (HCV)


In 2010, OraQuick HCV Rapid Antibody Test was approved by the U.S. FDA that became an alternative to enzyme immunoassay testing for HCV


Report Outline:

The report provides granular level information about the market size, regional market share and forecast from 2017-2023
The report covers in-detail insights about the competitor’s overview, key findings and their key strategies
The report outlines drivers, restraints, challenges, and trends that are currently faced by the industry
The report tracks recent innovations, key developments and startup’s details that are working in the industry
The report provides plethora of information about market entry strategies, regulatory framework and reimbursement scenario